Sarepta Therapeutics, Inc. $SRPT Shares Sold by Maryland State Retirement & Pension System

Maryland State Retirement & Pension System cut its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 18.3% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 4,233 shares of the biotechnology company’s stock after selling 945 shares during the period. Maryland State Retirement & Pension System’s holdings in Sarepta Therapeutics were worth $270,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of SRPT. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics during the 1st quarter valued at about $30,000. Center for Financial Planning Inc. acquired a new position in Sarepta Therapeutics during the 1st quarter valued at about $31,000. UMB Bank n.a. boosted its stake in Sarepta Therapeutics by 53.0% during the 1st quarter. UMB Bank n.a. now owns 797 shares of the biotechnology company’s stock valued at $51,000 after purchasing an additional 276 shares during the period. Logan Capital Management Inc. acquired a new position in Sarepta Therapeutics during the 4th quarter valued at about $61,000. Finally, Hurley Capital LLC boosted its stake in Sarepta Therapeutics by 139.2% during the 1st quarter. Hurley Capital LLC now owns 1,435 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 835 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of analyst reports. Baird R W lowered shares of Sarepta Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, July 18th. William Blair reissued an “outperform” rating on shares of Sarepta Therapeutics in a research note on Tuesday, July 29th. Citigroup initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, July 22nd. They set a “sell” rating for the company. Jefferies Financial Group reduced their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a research note on Thursday, July 24th. Finally, Wall Street Zen raised shares of Sarepta Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Six investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Hold” and an average target price of $43.63.

Sarepta Therapeutics Stock Down 3.8%

SRPT stock opened at $20.99 on Tuesday. Sarepta Therapeutics, Inc. has a 52-week low of $10.41 and a 52-week high of $144.22. The company’s 50 day simple moving average is $19.37 and its 200-day simple moving average is $52.46. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.89 and a quick ratio of 1.81. The firm has a market capitalization of $2.05 billion, a P/E ratio of -24.13 and a beta of 0.46.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $2.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.89 by $1.13. Sarepta Therapeutics had a negative net margin of 2.34% and a negative return on equity of 1.03%. The business had revenue of $611.09 million for the quarter, compared to analyst estimates of $530.66 million. During the same quarter in the previous year, the business earned $0.07 earnings per share. The firm’s revenue was up 68.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current year.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.